An interventional study of Placebo Group and CyanthOx™80 Group in Skin Aging, Hair and Scalp Health and Hair Loss, sponsored by Chia Nan University of Pharmacy ＆ Science. Completed at 1 site in Taiwan. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Chia Nan University of Pharmacy ＆ Science · Not applicable, Interventional, and Prevention
The goal of this clinical trial is to learn whether daily intake of CyanthOx™80 capsules can improve skin, scalp, hair, and selected blood biomarkers in healthy adults after 12 weeks.
Researchers will compare participants who take CyanthOx™80 with participants who take a placebo to evaluate its effectiveness and tolerability.
A total of 40 participants will be randomly assigned to the CyanthOx™80 group or placebo group, with 20 participants in each group. Participants will not know which capsule they receive.
Participants will:
Take one capsule daily for 12 weeks. Attend study visits at baseline and weeks 4, 8, and 12. Undergo non-invasive facial skin assessments at baseline, week 4, and week 12. Undergo scalp and hair assessments at baseline and weeks 4, 8, and 12. Provide a 10 mL blood sample at baseline and week 12 for tests related to antioxidant capacity, inflammation, aging, collagen, and blood lipids.
Complete questionnaires about skin condition and product satisfaction. Provide collected shed hair at weeks 4, 8, and 12. Have facial, scalp, and hair photographs taken. Identifiable areas will be masked before disclosure.
Before each skin or scalp assessment, participants will cleanse the test area with water and rest at room temperature for 30 minutes.
511 studies on the registry are indexed under Alopecia; 128 are open to participants now.
This study's enrollment of 40 is below the median of 50 across 430 interventional studies indexed under Alopecia.
Browse Alopecia studies →Chia Nan University of Pharmacy ＆ Science is the lead sponsor of 6 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will take one CyanthOx™80 capsule daily for 12 weeks.
Dietary Supplement: CyanthOx™80 Group
Participants will take one placebo capsule daily for 12 weeks.
Dietary Supplement: Placebo Group
Participants will take one placebo capsule daily for 12 weeks.
Participants will take one CyanthOx™80 capsule daily for 12 weeks.
Change in Blood Biomarkers (TEAC)
Changes in biomarkers related to antioxidant capacity using TEAC ELISA kits. Unit: μM
Time frame: Baseline and Week 12
Change in Hair and Scalp Condition (hair-root diameter)
Changes in hair-root diameter by using Mitutoyo, C/N293-100 Unit：percent change
Time frame: Baseline, Week 4, Week 8, and Week 12
Change in Hair and Scalp Condition (hair strength)
Changes in hair strength by using Hair Pull Test Unit：percent change
Time frame: Baseline, Week 4, Week 8, and Week 12
Change in Hair and Scalp Condition (hair elasticity)
Changes in hair elasticity measured using SHIMADZU EZ-SX Unit：percent change
Time frame: Baseline, Week 4, Week 8, and Week 12
Change in Hair and Scalp Condition (tensile strength)
Changes in tensile strength by using SHIMADZU EZ-SX Unit：percent change
Time frame: Baseline, Week 4, Week 8, and Week 12
Change in Hair and Scalp Condition (hair shedding)
Changes in hair shedding by collecting and counting hairs found in the shower drain unit：percent change
Time frame: Baseline, Week 4, Week 8, and Week 12
Change in Blood Biomarkers (SOD)
Changes in biomarkers related to antioxidant capacity measured using SOD ELISA kits. Unit: U/mL
Time frame: Baseline and Week 12
Change in Blood Biomarkers (GSH)
Changes in biomarkers related to antioxidant capacity using GSH ELISA kits. Unit: ng/mL
Time frame: Baseline and Week 12
Change in Blood Biomarkers (TNF-alpha)
Changes in biomarkers related to inflammation measured using TNF-alpha ELISA kits. Unit: pg/mL
Time frame: Baseline and Week 12
Change in Blood Biomarkers (Desmosine)
Changes in biomarkers related to aging measured using Desmosine ELISA kits. Unit: ng/mL
Time frame: Baseline and Week 12
Change in Blood Biomarkers (AGE)
Changes in biomarkers related to aging measured using AGE ELISA kits. Unit: μg/mL
Time frame: Baseline and Week 12
Change in Blood Biomarkers (HA)
Changes in biomarkers related to Hyaluronan content measured using HA kits. Unit: ng/mL
Time frame: Baseline and Week 12
Change in Blood Biomarkers (NAD/NADH)
Changes in biomarkers related to antioxidant capacity measured using NAD/NADH ELISA kits. Unit: μM/L
Time frame: Baseline and Week 12
Change in Blood Biomarkers (Collagen)
Changes in biomarkers related to collagen metabolism measured using Collagen ELISA kits. Unit: μg/mL
Time frame: Baseline and Week 12
Change in Blood Biomarkers (Telomerase)
Changes in biomarkers related to aging, measured using Telomerase ELISA kits. Unit: ng/mL
Time frame: Baseline and Week 12
Change in Blood Biomarkers (Total cholesterol)
Change in serum Total cholesterol levels measured using an automated clinical chemistry analyzer. Unit: mg/dL
Time frame: Baseline and Week 12
Change in Blood Biomarkers (TG)
Change in serum triglyceride levels measured using an automated clinical chemistry analyzer. Unit: mg/dL
Time frame: Baseline and Week 12
Change in Blood Biomarkers (HDL)
Change in serum high-density lipoprotein cholesterol (HDL-C) levels measured using an automated clinical chemistry analyzer. Unit: mg/dL
Time frame: Baseline and Week 12
Change in Blood Biomarkers (LDL)
Change in serum low-density lipoprotein cholesterol (LDL-C) levels measured using an automated clinical chemistry analyzer. Unit: mg/dL
Time frame: Baseline and Week 12
Facial Skin Analysis Parameters (skin spots)
VISIA Micro-Analysis Skin Image Analyzer was utilized to measure skin spots. Units: percetage change.
Time frame: Baseline, Week 4, and Week 12
Facial Skin Analysis Parameters (Wrinkle)
VISIA Micro-Analysis Skin Image Analyzer was utilized to measure Wrinkle. Units: percetage change.
Time frame: Baseline, Week 4, and Week 12
Facial Skin Analysis Parameters (Texture)
VISIA Micro-Analysis Skin Image Analyzer was utilized to measure Texture. Units: percetage change.
Time frame: Baseline, Week 4, and Week 12
Facial Skin Analysis Parameters (UV Spot)
VISIA Micro-Analysis Skin Image Analyzer was utilized to measure UV Spot. Units: percetage change.
Time frame: Baseline, Week 4, and Week 12
Facial Skin Analysis Parameters (Brown Spot)
VISIA Micro-Analysis Skin Image Analyzer was utilized to measure Brown Spot. Units: percetage change.
Time frame: Baseline, Week 4, and Week 12
Facial Skin Analysis Parameters (Red Area)
VISIA Micro-Analysis Skin Image Analyzer was utilized to measure Red Area. Units: percetage change.
Time frame: Baseline, Week 4, and Week 12
Facial Skin Analysis Parameters (Collagen)
DermaLab® Series SkinLab Combo was utilized to measure collagen. Units: percetage change.
Time frame: Baseline, Week 4, and Week 12
Facial Skin Analysis Parameters (Brightness)
Chroma Meter MM500 was utilized to measure Brightness. Units: percetage change.
Time frame: Baseline, Week 4, and Week 12
Facial Skin Analysis Parameters (Erythema)
Chroma Meter MM500 was utilized to measure Erythema. Units: percetage change.
Time frame: Baseline, Week 4, and Week 12
Facial Skin Analysis Parameters (Melanin)
Soft Plus was utilized to measure Melanin. Units: percetage change.
Time frame: Baseline, Week 4, and Week 12
Facial Skin Analysis Parameters (Skin Hydration)
Corneometer CM825 was utilized to measure Skin Hydration. Units: percetage change.
Time frame: Baseline, Week 4, and Week 12
Facial Skin Analysis Parameters (Skin Elasticity)
Soft Plus was utilized to measure Skin Elasticity. Units: percetage change.
Time frame: Baseline, Week 4, and Week 12
Facial Skin Analysis Parameters (Transepidermal Water Loss)
Tewameter TM300 was utilized to measure Transepidermal Water Loss. Units: percetage change.
Time frame: Baseline, Week 4, and Week 12
Plan to share: No
No publications or documents are linked to this record.
Ran from Nov 2025 to primary completion in Jan 2026, 2 months.
Of 85 non-industry interventional studies with no phase under Alopecia, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 46. This study's 2 months is below that.
Counting every sponsor, half of 146 studies reached it within 12 months; a quarter within 6 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chia Nan University of Pharmacy ＆ Science